Literature DB >> 26748507

Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases.

Suzie Seabroke1, Gianmario Candore2, Kristina Juhlin3, Naashika Quarcoo4, Antoni Wisniewski5, Ramin Arani5, Jeffery Painter4, Philip Tregunno6, G Niklas Norén3, Jim Slattery2.   

Abstract

INTRODUCTION: Disproportionality analyses are used in many organisations to identify adverse drug reactions (ADRs) from spontaneous report data. Reporting patterns vary over time, with patient demographics, and between different geographical regions, and therefore subgroup analyses or adjustment by stratification may be beneficial.
OBJECTIVE: The objective of this study was to evaluate the performance of subgroup and stratified disproportionality analyses for a number of key covariates within spontaneous report databases of differing sizes and characteristics.
METHODS: Using a reference set of established ADRs, signal detection performance (sensitivity and precision) was compared for stratified, subgroup and crude (unadjusted) analyses within five spontaneous report databases (two company, one national and two international databases). Analyses were repeated for a range of covariates: age, sex, country/region of origin, calendar time period, event seriousness, vaccine/non-vaccine, reporter qualification and report source.
RESULTS: Subgroup analyses consistently performed better than stratified analyses in all databases. Subgroup analyses also showed benefits in both sensitivity and precision over crude analyses for the larger international databases, whilst for the smaller databases a gain in precision tended to result in some loss of sensitivity. Additionally, stratified analyses did not increase sensitivity or precision beyond that associated with analytical artefacts of the analysis. The most promising subgroup covariates were age and region/country of origin, although this varied between databases.
CONCLUSIONS: Subgroup analyses perform better than stratified analyses and should be considered over the latter in routine first-pass signal detection. Subgroup analyses are also clearly beneficial over crude analyses for larger databases, but further validation is required for smaller databases.

Entities:  

Mesh:

Year:  2016        PMID: 26748507     DOI: 10.1007/s40264-015-0388-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  24 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

2.  The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.

Authors:  Victor V Gogolak
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Apr-May       Impact factor: 2.890

3.  Practical pharmacovigilance analysis strategies.

Authors:  A Lawrence Gould
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Oct-Nov       Impact factor: 2.890

4.  Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.

Authors:  Sandra de Bie; Katia M C Verhamme; Sabine M J M Straus; Bruno H Ch Stricker; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

5.  Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

Authors:  June S Almenoff; Karol K LaCroix; Nancy A Yuen; David Fram; William DuMouchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS).

Authors:  Emily Jane Woo; Robert Ball; Dale R Burwen; M Miles Braun
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports database.

Authors:  Ziad Zeinoun; Harry Seifert; Thomas Verstraeten
Journal:  Hum Vaccin       Date:  2009-09-07

8.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

9.  A general estimator for the variance of the Mantel-Haenszel odds ratio.

Authors:  J Robins; S Greenland; N E Breslow
Journal:  Am J Epidemiol       Date:  1986-11       Impact factor: 4.897

10.  Spontaneous reporting of adverse drug reactions. II: Uses.

Authors:  M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

View more
  11 in total

1.  A Computational Framework for Identifying Age Risks in Drug-Adverse Event Pairs.

Authors:  Zhizhen Zhao; Ruoqi Liu; Lei Wang; Lang Li; Chi Song; Ping Zhang
Journal:  AMIA Annu Symp Proc       Date:  2022-05-23

2.  Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.

Authors:  Lovisa Sandberg; Henric Taavola; Yasunori Aoki; Rebecca Chandler; G Niklas Norén
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

3.  Comment on "Central Demyelinating Diseases After Vaccination Against Hepatitis B Virus: A Disproportionality Analysis Within the VAERS Database".

Authors:  Carine Cohen; Annick Houdeau; Alena Khromava
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

4.  Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.

Authors:  Kristina Star; Lovisa Sandberg; Tomas Bergvall; Imti Choonara; Pia Caduff-Janosa; I Ralph Edwards
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-15       Impact factor: 2.890

5.  Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance.

Authors:  Jeremy D Jokinen; Rosalind J Walley; Michael W Colopy; Thomas S Hilzinger; Peter Verdru
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

6.  Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.

Authors:  Peter Arlett
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

7.  A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.

Authors:  Jean-Louis Montastruc; Pierre-Louis Toutain
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

8.  Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.

Authors:  Ola Caster; Yasunori Aoki; Lucie M Gattepaille; Birgitta Grundmark
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

9.  The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.

Authors:  Gianmario Candore; Sebastian Monzon; Jim Slattery; Loris Piccolo; Rodrigo Postigo; Xavier Xurz; Sabine Strauss; Peter Arlett
Journal:  Drug Saf       Date:  2021-12-08       Impact factor: 5.606

10.  Good Signal Detection Practices: Evidence from IMI PROTECT.

Authors:  Antoni F Z Wisniewski; Andrew Bate; Cedric Bousquet; Andreas Brueckner; Gianmario Candore; Kristina Juhlin; Miguel A Macia-Martinez; Katrin Manlik; Naashika Quarcoo; Suzie Seabroke; Jim Slattery; Harry Southworth; Bharat Thakrar; Phil Tregunno; Lionel Van Holle; Michael Kayser; G Niklas Norén
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.